First large-scale study reporting OS with Lu-PSMA-617 (Pluvicto) in clinical setting. Similar OS regardless of age, race/ethnicity, number or type of metastasis. Listen for my take on why real world data is so important for our older patients. Median age in study = 69 yo. #GU25 @DukeCancer